Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

BACKGROUND: Resistance is almost inevitable and is still a major obstacle in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Only limited relevant clinical studies evaluated the therapeutic effects by combing metformin and EGFR-TKIs in non-small cell lung cancer (NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ruoshuang, Jia, Yijun, Li, Xuefei, Zhao, Chao, Zhao, Sha, Liu, Sangtian, Liu, Yiwei, Chen, Donglai, Zhang, Qian, Liu, Xiaozhen, Shi, Jinpeng, Li, Jiayu, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044488/
https://www.ncbi.nlm.nih.gov/pubmed/33889509
http://dx.doi.org/10.21037/tlcr-20-1153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044488/
https://www.ncbi.nlm.nih.gov/pubmed/33889509
http://dx.doi.org/10.21037/tlcr-20-1153

Ejemplares similares